Stopping the hemorrhage
Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD Congress in Rome, where Inspiration is also headquartered. The drug, an intravenous recombinant Factor IX product, safeguarded major surgical measures by guaranteeing effective hemostasis. It has now completed pivotal Phase III clinical testing in the US, Europe, Israel and India.